Sep 18 Love0 FDA grants Fast Track Designation for SPI-1005 in the Treatment of Meniere’s Disease By Jim News Short SEATTLE — Sound Pharmaceuticals is pleased to announce that the FDA’s Division of Neurology Products has granted its request for Fast Track Designation (FTD) involving SPI-1005 in the treatment of Meniere’s Disease (MD). Read More
Jun 25 Love0 Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere’s Disease clinical trial By Jim News Short SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo Read More
Mar 20 Love0 Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial By Jim News Short Read More
Jan 14 Love0 Sound Pharmaceuticals advances Phase 2 hearing loss clinical trial in Cystic Fibrosis By Jim News Short Read More
Oct 18 Love0 Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study By Jim News Short Read More
Nov 01 Love0 University of Oxford and Sound Pharmaceuticals begin Phase 2 clinical trial on novel treatment for bipolar disorder By Jim News Short Read More
Oct 03 Love0 Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Meniere’s Disease By Jim News Short Read More
Sep 29 Love0 Enrollment Underway in CF Clinical Trial for Ear Toxicity Caused by Antibiotics By Jim News Short Read More
Jun 29 Love0 Sound Pharmaceuticals completes enrollment on Meniere’s Disease clinical trial By Jim News Short Read More
Mar 20 Love0 Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use By Jim News Short Read More
